期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

药物基因与个体化给药 被引量：3

原文传递
导出
摘要 目的综述近年来基因研究在药物治疗方面的应用。方法查阅国内外大量文献,并进行总结归纳。结果与结论药物遗传学为个体化治疗开辟了新的思路。合理利用基因信息将更加准确地预见药物疗效,选择适当的药物治疗方案,降低药物毒性和不良反应风险。依据患者基因组特征优化治疗方案,能真正做到因人而异。
作者 叶敏 付强 朱珠
机构地区 中国医学科学院北京协和医学院北京协和医院药剂科
出处 《中国药学杂志》 CAS CSCD 北大核心 2009年第9期645-648,共4页 Chinese Pharmaceutical Journal
关键词 基因多态性 药物不良反应 个体化给药
分类号 Q789 [生物学—分子生物学] R969.3 [医药卫生—药理学]
  • 相关文献

参考文献30

  • 1EVANS W E, RELLING M V. Moving towards individualized medicine with pharmacogenomics[J]. Nature, 2004, 429(6990): 464-468.
  • 2WEINSHILBOUM R. Inheritance and drug response[J]. N Engl J Med, 2003, 348(6): 529-537.
  • 3BEUTLER E. Drug-induced hemolytic anemia[J]. Pharmacol Rev, 1969, 21(1): 73-103.
  • 4DE MESTIER P, DES GUETZ G. Treatment of gastrointestinal stromal tumours with imatinib Mesylate: a major breakthrough in the understanding of tumor? specific molecular characteristics[J]. World JSurg, 2005, 29(3): 357-362.
  • 5PATEL S, ZALCBERG J R. Optimizing the dose of imatinib for treatment of gastrointestinal stromal tumours: lessons from the phase 3 trials[J].Eur J Cancer, 2008, 44(4): 501-509.
  • 6SAVAGE D G, ANTMAN K H. Imatinib mesylate-a new oral targeted therapy[J].N Engl J Med, 2002, 346(9): 683-693.
  • 7DEMETRI G D, MEHREN M V, BLANKE C D, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors[J].N Engl J Med, 2002, 347(7): 472-480.
  • 8MITSUDOMI T, YATABE Y. Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer[J].Cancer Sci, 2007, 98(12): 1817-1824.
  • 9SLAMON D J, GODOLPHIN W, JONES LA, et al. Studies of the HER-2/neu Proto-oncogene in human breast and ovarian cancer [J]. Science, 1989, 244(4905): 707-712.
  • 10YAMAMOTO D, IWASE S, KITAMURA K, et al. A phase Ⅱ study of trastuzumab and capecitabine for patients with HER2-overexpressing metastatic breast cancer: Japan Breast Cancer Research Network (JBCRN) 00 Trial [J]. Cancer Chemother Pharmacol, 2008, 61(3): 509-514.

同被引文献35

  • 1于建江.浅谈天人合一对中医整体观的体现[J].新疆中医药,2004,22(3):4-4. 被引量：6
  • 2聂玉梅,钟睿.循证医学在肿瘤治疗中的应用[J].实用癌症杂志,2006,21(3):329-332. 被引量：6
  • 3刘宝瑞.努力探索肿瘤的个体化药物治疗[J].医学研究生学报,2007,20(11):1121-1122. 被引量：11
  • 4Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015 [J]. CA Cancer J Clin, 2015, 65(1): 5-29. doi: 10.3322/ caae,21254.
  • 5Wang LR1, Huang MZ, Zhang GB, et aL Phase II study of gemcitabine and earboplatin in patients with advanced non- small-cell lung cancer [J]. Cancer Chemother Pharrnacol, 2007, 60(4): 601-607.
  • 6Wang L, Wu X, Huang M, et al. The efficacy and relation- ship between peak concentration and toxicity profile of fixed-dose-rate gemeitabine plus earboplatin in patients with advanced non-small-cell lung cancer [J]. Cancer Che- mother Pharmacol, 2007, 60(2): 211-218.
  • 7Gonlugur U, Pinarbasi H, Gonlugur TE, et al. The associa-tion between polymorphisms in glutathione S-transferase (GSTM1 and GSTY1) and lung cancer outcome [J]. Cancer Invest, 2006, 24(5): 497-501.
  • 8Davidson JD, Ma L, Flagella M, et al. An increase in the expression of ribonucleotide reductase large subunit 1 is as- sociated with gemcitabine resistance in non-small cell lung cancer cell lines [J]. Cancer Res, 2004, 64(11): 3761-3766.
  • 9Gray J, Simon G, Bepler G. Molecular predictors of chemo- therapy response in non-small-cell lung cancer [J]. Expert Rev Anticancer Ther, 2007, 7(4): 545-549.
  • 10Sanger F, Nicklen S, Coulson AR. DNA sequencing with chain-terminating inhibitors. 1977 [J]. Biotechnology, 1992, 24: 104-108.

引证文献3

二级引证文献7

中国药学杂志
2009年 第9期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部